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1. Introduction 
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible vision 
impairment in developed countries (Friedman et al., 2004; Klein et al., 1992). Although an 
estimated 80% of patients with AMD have the non-neovascular form, the neovascular form 
is responsible for almost 90% of severe visual loss (visual acuity 20/200 or worse) resulting 
from AMD (Ferris et al., 1984). There was no effective treatment for most of the neovascular 
AMD lesions till 2004. By this time, the role of vascular endothelial growth factor (VEGF) in 
neovascular AMD became obvious and anti-VEGF agents emerged for this purpose. 
Pegaptanib sodium intravitreal injection (Macugen; [OSI] Eyetech, New York, NY, 2004), 
ranibizumab intravitreal injection (Lucentis, Genentech, Inc., South San Francisco, CA, 2006) 
were the FDA approved treatments for AMD. The first report of intravitreal bevacizumab 
(Avastin; Genentech, Inc., South San Francisco, CA) administration for neovascular AMD 
was published in 2005 (Rosenfeld et al., 2005). By early 2006, off-label intravitreal 
bevacizumab was used by many retina specialists as a first-line therapy for neovascular 
AMD because of the low cost of this drug. Wholesale prices of the medications range from 
$1950 per dose for ranibizumab and $995 per dose for pegaptanib, to approximately $50 per 
dose for bevacizumab (Champan & Beckey, 2006; Web, 2008).  
MARINA and ANCHOR were the first studies showing level 1 evidence for the effect of 
ranibizumab for the treatment of neovascular ARMD (Brown et al., 2009; Rosenfeld et al., 
2006a; Rosenfeld et al., 2006b). These studies have shown that 33-40% of the eyes with 
neovascular AMD treated with ranibizumab gained 15 letters or more (Brown et al., 2009; 
Rosenfeld et al., 2006a). However these studies used monthly injections of the drug for 24 
months. This is the most effective treatment but almost impossible to apply in routine 
applications both for patients and doctors. Additionally monthly injections will cost so 
much that treatment cannot be afforded neither by patients nor the social security systems.  
2. How to decrease the number of injections without compromising visual 
acuity? 
PIER study was the first study investigating the results of less frequent dosing regimens 
with ranibizumab (3-monthly) for the treatment of AMD (Regillo et al., 2008). However 
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PIER study revealed disappointing results showing loss of early gained vision during 3-
monthly injection period. Other prospective studies, PrONTO and SUSTAIN, investigated 
the efficacy of PRN (pro re nata; as needed) treatment regimen. Results from these studies 
suggested that fewer injections by using a variable dosing regimen with OCT will most 
likely result in visual acuity improvements similar to the results from the phase III trials 
which used monthly injections (Holz et al., 2011; Lalwani et al., 2009; Rosenfeld et al., 2006b) 
2.1 What is “PRN” treatment regimen and what are the most reliable criteria for 
treatment decision? 
PRN treatment regimen is a treatment schedule which allows treatment only if the lesion is 
active. The aim of the PRN treatment is to avoid monthly injections and to decrease the 
number of injections as much as possible while preserving the vision gained in the loading 
period (first three months).  
The key point in PRN treatment is assessment of the activity of the lesion to decide for 
additional treatments. It is obvious that a totally fibrotic yellow scarring lesion without any 
hemorrhage around, only late staining of the scar tissue in fluorescein angiography (FA), 
and no subretinal or intraretinal fluid in optical coherence tomography (OCT) with stable 
vision for a long time does not need any treatment. On the other side of the spectrum, a 
lesion with subretinal hemorrhages all around, significant late leakage in FA and a 
considerable subretinal or intraretinal fluid in OCT and deteriorating vision recently needs 
treatment with no doubt. However most of the lesions are in between these two ends of the 
spectrum especially during the course of anti-VEGF treatments and may be difficult to 
decide if any further treatment is necessary or not.  
Until recently, the presence or absence of fluorescein leakage and the angiographic 
appearance of the lesion were the main criteria for the decision to treat neovascular 
ARMD and re-treat using PDT or anti-VEGF therapy (Schmidt-Erfurth et al., 2007). Within 
the last decade OCT has emerged and enhanced our understanding in many central 
retinal diseases. For AMD, OCT appears to be useful for evaluating the responses of the 
retina and retinal pigment epithelium (RPE) to the treatment (Cohen et al., 2007; Eter & 
Spaide, 2005; Fung et al., 2007; Krebs et al., 2008; Lalwani et al., 2009; Salinas-Alamán et 
al., 2005; Schmidt-Erfurth et al., 2007; van Velthoven et al., 2006;). Clinical trials have 
shown that in the two thirds of patients requiring ranibizumab therapy because of 
recurrent neovascularization, OCT seemed to detect early anatomic changes in the macula 
before any vision loss (observation during the extension trials of phase I-II studies by P. 
Rosenfeld: unpublished data). The PrONTO study was initiated to explore the use of OCT 
as the basis for a less frequent variable dosing regimen with ranibizumab (Fung et al., 
2007; Lalwani et al., 2009). This study used some criteria for retreatment including an OCT 
based parameter (an increase in central OCT thickness of at least 100 mm) during the first 
year. However they made an amendment to their OCT based criteria in the second year. 
They changed the retreatment criteria to include any qualitative change in the appearance 
of the OCT images that suggested recurrent fluid in the macula. These qualitative changes 
included the appearance of retinal cysts or subretinal fluid or an enlargement of a PED. 
Any of these qualitative changes alone was sufficient to permit retreatment (Lalwani et 
al., 2009). 
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2.2 Treatment regimens other than PRN 
Although PRN treatment regimen may reduce the number of intravitreal injections and 
allow the treatment plan to be individualized, it may still require monthly visits to 
specialized centers. In contrast to mandated monthly injections, patients treated with PRN 
strategies may develop multiple recurrences of CNV activity over time. Recurrent intra- or 
subretinal fluid could potentially induce progressive, cumulative dysfunction of the neural 
retina, resulting in a decreased ability of the retina to recover despite further treatment. 
There are some other treatment regimens like “treat and extend” and “individualized 
injection intervals” regimens which aim to individualize the treatment plan and decrease the 
number of injections per year, but at the same time attempts to achieve a fluid-free macula 
and decrease the number of visits (Brown & Regillo, 2007; Gupta et al., 2010; Hörster et al., 
2011; Oubraham et al., 2011; Spaide, 2007). 
2.2.1 Treat & extend dosing regimen  
In an attempt to minimize the number of intravitreal injections, office visits, and ancillary 
testing, a “treat and extend” regimen (TER) was first put forth by Bailey Freund, 
(unpublished data, February 2006) and then adopted by others (Gupta et al., 2010; 
Oubraham et al., 2011). A typical TER starts with monthly injections until the signs of 
exudation have resolved with confirmation by OCT. The treatment interval is then 
sequentially lengthened by 1 to 2 weeks as long as there are no signs of recurrent 
exudation. When recurrent exudation is detected on a follow-up visit, the treatment 
interval is reduced to the prior interval. Treatment is rendered at every visit but the time 
between visits is individualized based on a given patient’s response to treatment. As with 
traditional PRN regimens, the goal is to maintain an exudation-free macula with the 
fewest number of injections. This approach also may allow for a significant reduction in 
office visits and tests. 
In a study by Gupta et al., eyes with neovascular AMD experienced significant visual 
improvement when managed with intravitreal ranibizumab using a TER. This treatment 
approach also was associated with significantly fewer patient visits, injections, and direct 
annual medical cost compared with monthly injections such as in the phase III clinical trials 
(Gupta et al., 2010). The interval was individualized for each patient in an attempt to 
maintain an exudation-free macula. In another study comparing the results of this treatment 
regimen with the standard PRN regimen, patients reinjected by the TER had a far better 
visual outcome than PRN regimen but needed more injections (Oubraham et al., 2011). 
2.2.2 Individualized injection intervals 
Another individualized treatment strategy that aims to avoid recurrent CNV activity in 
addition to reducing the number of injections and visits may be to perform the injection 
immediately prior to the next recurrence. This would require the ability to determine or 
predict the recurrence interval for an individual patient. A treatment schedule can be 
obtained for some of the cases after a couple of years of experience with PRN regimen 
(Hörster et al., 2011). Knowledge of individual recurrence interval times may allow for the 
development of an individualized treatment plan (Figure 1). 
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Fig. 1. A, Baseline, VA: 44 letters, 1st injection. B, 1st month, 53 letters, 2nd injection. C, 2nd 
month, 54 letters, 3rd injection. D, 51 letters, no treatment. E, 4th month, 46 letters, 4th 
injection. F, 5th month, 47 letters, no treatment. G, 6th month, 46 letters, 5th injection. H, 7th 
month, 42 letters, 6th injection. I, 8th month, 50 letters, no treatment. J, 8th month, 44 letters, 
7th injection. K, 9th month, 48 letters, no treatment. L, 10th month, 38 letters, 8th injection. 
According to the data, this patient has a recurrence pattern of 8 weeks, thus needs re-
treatment every 7 weeks. 
A retrospective study in University of Cologne analyzed the recurrence intervals of patients 
undergoing anti-VEGF therapy for neovascular AMD to determine whether predictable, 
regular recurrence patterns were present for individual patients (Hörster et al., 2011). The 
paper reported that, all recurrences occurred at regular intervals in 41% of the eyes and the 
recurrence interval time may vary between individuals (Hörster et al., 2011). 
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In conclusion, re-injections of ranibizumab shortly prior to a recurrence may avoid recurrent 
leakage and fluid accumulation, as well as further growth of the CNV lesion size. Therefore, 
avoiding recurrent CNV activity with prophylactic injections may protect the neural retina 
from additional damage and improve the long-term prognosis. However, this approach 
requires the ability to determine individual recurrence intervals with a couple of years of 
experience with PRN regimen. 
2.3 The need for an activity scoring for re-treatment of exudative AMD 
All treatment regimens mentioned above aims to reduce injection numbers without 
compromising the patients visual acuity. Yet there is not a consensus about the objective 
criteria of an active neovascular CNV lesion. 
Definition of an active lesion should not be done only with the OCT based criteria. We 
believe that, other parameters like visual acuity, presence of hemorrhage associated with the 
lesion, lesion size and FA staining pattern (when needed) are all also important for 
assessment of neovascular AMD activity. The PrONTO study put some of these parameters 
together and created their criteria for retreatment. Retreatment with ranibizumab was 
performed only if one of the following occurred in PrONTO study (Fung et al., 2007): 
1. An increase in central OCT thickness of at least 100 mm,  
2. A loss of five letters in conjunction with recurrent fluid by OCT,  
3. New-onset classic neovascularization, 
4. New macular hemorrhage. 
SUSTAIN study used only VA and OCT criteria for retreatment decision. We believe that 
these are very well prepared criteria, however, some of the items could be changed and 
some new criteria could be added to make it more reliable.  
3. A clinical activity scoring for re-treatment of exudative AMD 
A new clinical activity scoring (AS) is proposed to assess activity of lesions, to quantify the 
activity for statistical purposes in clinical studies and to standardize the re-treatment 
protocols during the course of anti-VEGF treatments of neovascular AMD lesions. This may 
be a basis for treatment regimens. 
3.1 Methods 
The proposed AS is based on the well known and widely used signs and findings of active 
neovascular AMD (Table 1):  
1. Presence of subretinal or intraretinal fluid in OCT,  
2. Presence of hemorrhage associated with the lesion,  
3. Change in vision; 
a. Objective measured visual acuity (VA)  
b. Subjective vision (what patient feels about his vision)  
4. Change in size of the lesion,  
5. FA staining pattern (when needed). 
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PARAMETER GRADING SCORE
Hemorrhage 
Amount of hemorrhage 
associated with the lesion 
No hemorrhage 0
decreased 1
Same amount 2
increased 3
OCT 
Subretinal fluid / retinal 
thickening / PED 
None 0
Decreased 1
Any amount at beginning / Stable 2
Increased 3
Visual assessment 
Objective 
Increased 0
No change 1
Decreased 2
Visual assessment  
Subjective 
Increased 0
No change 1
Decreased 2
FA 
Staining pattern 
No staining/window defect 0
Staining of scar tissue/PED 1
Late leakage 2
Size of the lesion  
Lesion area in FA 
Decreased 0
Beginning size / Stable 1 
Increased  2 
Table 1. Clinical Activity Scoring for neovascular AMD lesions 
Apart from FA staining pattern, all of the other assessments are based on the changes (same-
baseline/increased/decreased) in each parameter and given a number to define the activity. 
At the end of the assessment, given numbers are summed and an activity score is calculated. 
This scoring has been used in a group of neovascular AMD patients all of which have been 
involved in a prospective study for intravitreal bevacizumab (IVB) in our clinic (Şekeryapan 
et al., 2011). All of them received IVB monotherapy. The reports of the patients were 
reviewed retrospectively and demographic features as well as lesion characteristics of the 
patients were noted. AS of all of the lesions were calculated according to the following 
criteria: 
1.  OCT: OCT was performed using the Humphrey model 3000 (Zeiss-Humphrey 
Instruments, San Leandro, CA). After pupil dilatation, six consecutive 6mm long scans 
containing 128 axial profiles (A-scans) at equally spaced angular orientations in a radial 
spoke pattern centered on the fovea (known as Fast Macular Thickness Protocol) were 
obtained for each eye. Using Retinal Thickness Mapping Software mean retinal 
thickness value which was measured in the central disc with a diameter of 1000µm in 
the center of the macula was used as central foveal thickness (CFT). The fluid pattern 
(subretinal / intraretinal diffuse / cystoid / pigment epithelial detachment - PED) was 
also noted. Only the CFT was used as an activity parameter in AS and at least 10% 
increase or decrease in CFT was accepted as a decrease or increase. The amount of fluid 
at the beginning was scored as 2. It was scored as “0” if there is no fluid, “1” if there is a 
decrease and “3 if there is an increase in CFT. 
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2. Amount of hemorrhage: The amount of hemorrhage associated with the lesion (in 
ophthalmoscopy, colored fundus photography or FA) was noted and if there is any 
hemorrhage at the beginning it was scored as 2. If there is no hemorrhage it was scored 
as 0, if it was decreased it was scored as 1, if it was the same, scored as 2, and if it was 
increased scored as 3. 
3. Visual assessment:  
a. Objective VA is measured with ETDRS and noted as a baseline and scored as 1. If 
there is a decrease in vision (any line or ≥5 letters loss) it was scored as 2 and if 
there is any increase in vision (any line or ≥5 letters gain) it was scored as 0.  
b. Subjective vision (what patient feels about his vision): Patient’s feeling about any 
change in his vision was also asked and noted as subjective vision which was 
scored as 0 if he feels better, 2 if he feels worse and 1 if he did not feel any change 
(baseline). 
4. FA staining pattern: No staining or window defect (0), staining of scar tissue or PED (1) 
and late leakage (2) were noted.  
5. The area of the lesion (mm2): It was measured in FA and the baseline area (or no 
change) was scored as 1, at least 10% (of the original area) increase was scored as 2 and 
at least 10% decrease was scored as 0. 
Records of the patients at the 1st month visit after the treatment were also noted and all of 
the above parameters were again noted, so that an AS is calculated both before and after the 
treatment. AS could range between 0 and 14. Change in AS after the treatment was analyzed 
by using Wilcoxon signed rank test.  
It can be hypothesized that, the more active the lesion the more it may respond to the anti-
VEGF therapy. A possible correlation between pretreatment AS and posttreatment decrease 
in AS was investigated by using Pearson correlation test to test this hypothesis. 
Eyes with favorable treatment response (two or more units of decrease in AS) and 
unfavorable treatment response (one unit or no decrease in AS) were separated and the 
mean pre and posttreatment AS were calculated for both groups. The mean AS of these two 
groups were compared by using Mann-Whitney U test. At this stage, a cut off point for AS 
was searched to determine the eyes that need treatment. Sensitivity, specificity, negative and 
positive predictive values of the AS were calculated to determine the cut off point for AS 
which will be used to decide on re-treatments. 
3.2 Results 
In this section, the results of an ongoing study is presented to better understand the activity 
scoring. 
A total of 52 eyes with neovascular AMD were involved in the study. Mean age of the 
patients was 72.7 (52-89), mean visual acuity (logMAR) was 0.68 (0-1.6) and mean lesion 
area was 8.9 mm2 (0.6-33mm2) before treatment. 
Pretreatment mean AS of eyes was 7.4 (ranged between 3 and 10) which decreased 
significantly to 4.2 after treatment (p<0.001, Wilcoxon). There was a significant positive 
correlation between the pretreatment AS of eyes and the posttreatment decrease in AS 
(Pearson correlation coefficient: 0.534, p<0.001, Figure 2).  
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Fig. 2. Correlation between the pretreatment AS of eyes and the post-treatment decrease in 
AS (Pearson correlation coefficient: 0.534, p<0.001) 
To define a cut-off point a group of eyes with favorable treatment responses is formed by 
separating those who had at least 2 point decrease in AS and named the favorable response 
group. The remaining eyes formed the unfavorable response group. The pretreatment mean 
AS was 7.5 (6-10) in favorable response group and 6 (3-7) in unfavorable response group. 
The pretreatment AS in favorable treatment response group was statistically significantly 
higher than those of unfavorable treatment response groups (p=0.003, Figure 3). 
The sensitivity, specificity, negative and positive predictive values of the AS with different 
cut off points were calculated (table 2) and an AS of 7 was found to be most suitable as a cut-
off point for further analysis. 
 
 
Pretreatment 
AS≥ 6 
Pretreatment 
AS≥ 7 
Pretreatment 
AS≥ 8 
Positive predictive value 85,10% 90,20% 100,00% 
Negative predictive value 40,00% 45,50% 25,70% 
Sensitivity 93,00% 86,00% 39,50% 
Specificity 22,20% 55,60% 100,00% 
Table 2. Predictive values, sensitivity and specificity of AS for detecting favorable treatment 
response (2 or more decrease in AS) 
Eyes with an AS of 7 or more (group 1, highly active group, n=41) were separated from 
those less than 7 (group 2, less active group, n=11) and a subgroup analysis was done. The 
mean AS in group 1 was 7.8 (7-10) before treatment and 4.3 (1-10) after treatment. The 
www.intechopen.com
 
Re-Treatment Strategies for Neovascular AMD: When to Treat? When to Stop? 
 
151 
decrease was statistically significant (p<0.001, Figure 4). The mean pretreatment AS was 5.4 
(3-6) in group 2 which decreased to 4 (1-6) after treatment. Although the decrease was less 
than that in group 1, it was still statistically significant (p=0.034, Figure 4). The mean 
decrease in AS was 3.5 in group one and 1.4 in group two (p=0.003, Figure 5).  
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Fig. 3. The pretreatment AS was statistically significantly higher in favorable treatment 
response group than unfavorable treatment response group (Mann Whitney U test p=0.003). 
Sensitivity of AS (ratio of eyes with a favorable response and an AS of 7 or more to the total 
number of eyes with favorable response) was 86% and, specificity of AS (ratio of eyes with 
an unfavorable response and an AS of less than 7 to the total number of eyes with 
unfavorable response) was 56% with a cut-off point of 7 (table 3). Positive predictive value 
(ratio of eyes with AS of 7 or more and a favorable response to the total number of eyes with 
AS of 7 or more) of AS was 90% and negative predictive value (ratio of eyes with AS of less 
than 7 and an unfavorable response to the total number of eyes with AS of less than 7) of AS 
was 45% (table 3). These may be assumed as indicators for accuracy of AS. 
 
 Favorable Response Unfavorable Response Total 
AS ≥7 37 4 41 
AS <7 6 5 11 
Total 43 9 52 
Positive predictive value, 37 of 41 = 90%; negative predictive value, 5 of 11 = 45%, sensitivity,  
37 of 43 = 86%, specificity, 5 of 9 = 56%. 
Table 3. Accuracy of activity score (AS) in predicting therapeutic outcome of treatment in 
neovascular AMD. 
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Fig. 4. Pretreatment and posttreatment mean AS of eyes in group 1 (with an AS of 7 or more, 
highly active group) and in group 2 (with an AS of less than 7, less active group). 
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Fig. 5. Pre and post treatment difference in AS of highly active group and less active group. 
Decrease in AS was significantly more in highly active group (pretreatment AS≥7) (p=0.003). 
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4. Discussion 
Neovascular AMD activity is an important factor to determine if it should be treated or 
not. It is important not to over-treat these eyes to avoid from injection and drug related 
complications as well as high cost of the treatment. There is no standard protocol for the 
treatment and retreatment schedule of these eyes and most ophthalmologists use their 
clinical experience to decide. Following the disappointing results from the quarterly 
regimen of the PIER study, which showed us loss of early gained vision during 3-monthly 
injection period (Regillo et al., 2008), new prospective studies like PrONTO, and 
SUSTAIN are under way investigating less frequent dosing regimens and preliminary 
results from these studies suggest that fewer injections (mean: 9.9 injections within 24 
months in PrONTO, 5.7 injections within 12 months in SUSTAIN) will most likely result 
in visual acuity improvements similar to the results from the phase III trials by using a 
variable dosing regimen with OCT (Fung et al., 2007; Lalwani et al., 2009; Rosenfeld et al., 
2006b).  
Although most of the studies used OCT findings and VA changes to determine the need for 
additional therapy (Holz et al., 2011), we believe that, some other parameters like, subjective 
feeling of patients about their vision, presence of hemorrhage associated with the lesion, 
lesion size, FA staining pattern and are also important for assessment of neovascular AMD 
activity especially in those undetermined cases.  AS is defined to standardize the 
understanding of findings and definition of active lesion. We are studying on this system 
since 2002 and have used it in our practice as well as in some of our studies (Ozdek et 
al.,2005; Ozdek et al.,2007).  
It is obvious that ophthalmoscopic appearance of a lesion is very important during 
interpretation of OCT and FA findings. This is to see new subretinal hemorrhages, exudates 
and fibrotic scar tissues so that FA and OCT findings can correctly be interpreted. OCT is a 
very important indicator of neovascular AMD activity and may be assumed as the main 
determinant for deciding the need for re-treatment in patients with AMD. Recently, there is 
a tendency to assess the activity of neovascular AMD lesions with only OCT without 
performing FA after the initial assessment (Brown & Regillo, 2007; Cohen et al., 2007; 
Rosenfeld et al., 2006b; Salinas-Alamán et al., 2005). This approach has emerged especially 
after anti-VEGF treatments of neovascular AMD lesions to avoid from monthly FA. Once 
the diagnosis of neovascular AMD was established with FA before treatment, OCT was 
reported to have a sensitivity of 96% for detecting lesion activity and a diagnostic efficiency 
(proportion of correct results) of 83% (Salinas-Alamán et al., 2005). However, OCT cannot 
detect other features including blood, lipid, and vascular patterns so effectively. When a 
subretinal new hemorrhage associated with the lesion appears in an eye with a dry OCT and 
FA (without any late leakage) most of the retina specialists assume it as an active lesion and 
treat it. This is the case when activation takes place on a far edge of the subfoveal 
neovascular AMD lesion. Salinas et al reported that, OCT may be complementary to FA, 
especially in cases in which FA was inconclusive. They have found that OCT was 
considered as positive (presence of sub-retinal fluid and/or intraretinal fluid) in 14.2% of the 
cases in which FA did not show clear leakage. On the other hand, most of the cases with 
positive OCT findings without any leakage on FA (false positives) had a disciform scar with 
persistent cystic cavities on OCT (Salinas-Alamán et al., 2005). It can be concluded that if 
there is no fibrotic scar visible during the fundus examination, the presence of remaining 
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fluid on the OCT scan may indicate residual lesion activity. It is also valid to assume that a 
hyperreflective structure on OCT could be misinterpreted without a fundus examination. 
Therefore, we believe that OCT, FA, and a fundus examination are complementary 
examinations that should be interpreted together in those undetermined cases. 
Although we used FA as a parameter in AS, we do not mean to say that we have to perform 
FA at every visit. Actually, we need to score the lesion only if it is not so clear that the lesion 
is active or not what we call as “undetermined cases”(Figure 6) . In other words, if we are 
not sure that a patient should be retreated or not, we can apply to the AS just to bring all the 
parameters together. If we still do not want to perform a FA, we can add only 1 point for FA 
which is neutral for activity scoring for FA. 
 
Fig. 6. 85 year old woman with a neovascular AMD on the left eye received four doses of 
intravitreal bevacizumab. On the last visit she had lost 5 letters with a subjective visual 
impairment. A, early phase of the angiogram. B, late phase of the angiogram. C, fundus 
photograph. D, OCT image of fovea. This would be an undetermined case without FA. 
Although the OCT has no sign of active lesion, there are late leakage in FA and objective and 
subjective visual loss. According to table 1 the patient has an activity score of 8 and assessed 
as an active lesion. 
Change in VA is another very important determinant factor in assessment of treatment 
effect on neovascular AMD. Usually worsening of VA is a sign of bad response to the 
treatment and, a stable or increased VA is supposed as a favorable treatment response. It is 
possible to see patients with a dry OCT and silent ophthalmoscopy without any hemorrhage 
having a decreased VA both objectively and subjectively. Those patients may have a late 
leakage in FA indicating activity and treatment need or that VA decrease may be a sign of 
progression of dry component of AMD.  
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Vision is not only the central VA and it has many other components like scotomas in 
visual field, contrast sensitivity, color vision etc. So snellen or ETDRS visual acuity 
measurement may not be enough to assess vision especially in macular diseases. The 
simplest measure may be to ask the patient his feelings about his vision; if it is the same, 
decreased or increased. The subjective change in vision may also give important clues 
about the effect of treatment. However, it is highly dependent on the patients’ personality 
and on the eye (in the better eye or in the worse eye). Patient may feel always worse if he 
is pessimistic and depressive or vice versa. Patient may feel the changes more precisely if 
the problem is in the better eye, on the other hand, may not feel the significant changes if 
the disease is in the worse eye. To overcome such shortcomings of subjective assessment 
of vision, more objective measures for the assessment of the other components of the 
central vision may be used. VFQ25 may be an option but takes a long time for these cases 
and is not so practical. Unver et al have developed a new tool for the automated 
assessment of functional central vision called central field acuity perimetry to solve such 
problems (Unver et al., 2009). However there is no clinical study with central field acuity 
perimetry for this purpose up till now. Microperimetry and functional magnetic 
resonance imaging are other new tools to measure objective measure of topographic 
visual function (Baseler et al., 2011; Uppal et al., 2011). On the other hand, deterioration of 
vision is not always an indication of lesion activity itself. Progression of the dry 
component of the disease (atrophic changes), fibrosis and cicatrisation of the lesion during 
healing period following treatment may also cause deterioration of vision. Vision cannot 
be a sole criterion (just like other parameters) but may add to other factors indicating 
lesion activity.  
Change in lesion area is another important determinant of the activity of the lesion. It is not 
seldom to see a central inactive lesion without any fluid in OCT or any change in objective 
measured VA may enlarge with a pseudo-pod like extension from one side indicating an 
active lesion. They usually feel this difference as a subjective worsening of the vision.  On 
the other side, the lesion area may become smaller after treatment indicating a decreased 
activity of the lesion. This is also an important complementary parameter for assessment of 
lesion activity and the response to treatment that needs to be taken into account during 
assessment especially in those gray cases. 
The major problem that we faced during the assessment of the reliability of this scoring 
system was the absence of a gold standard to define an active lesion which can be used for 
comparison. Rosenfeld et al were the first to define some criteria to identify an active lesion 
which needs retreatment with anti-VEGF agents in PrONTO study (Ozdek et al., 2005; 
Rosenfeld et al., 2006b). However, these criteria were not tested for reliability or sensitivity. 
Our scoring system has some differences from the criteria used in PrONTO study. Firstly, 
we used a 10% change in CFT in OCT to be significant instead of 100 micron increase for all 
cases. Sometimes only 30 microns of increase in CFT may be an important change 
(especially in minimally edematous fovea) on the other hand, even 100 microns of increase 
in OCT may be meaningless (especially in highly edematous/elevated fovea). Secondly, we 
have added change in size of the lesion as another criterion. Thirdly, we used subjective 
changes in vision as another criterion to decide on retreatments. This is because most of the 
patients feel some very early changes in lesion activity before any change become apparent 
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in FA, OCT or ETDRS visual acuity testing. We strongly believe that this should be taken 
into account during assessment of lesion activity. 
We would like to emphasize on the unequal distribution of points between different 
parameters of the AS. We have purposefully given higher scores for hemorrhage (3 points), 
OCT (3 points) and VA (2+2 points) which are more powerful indicators of the lesion 
activity than the FA and lesion size.  
When we take all of these parameters into account and score it, we observed that 
pretreatment mean AS was 7.4 which decreased significantly to 4.2 after treatment. Which 
means that AS really indicates the activity of the lesion. We also observed that a lesion with 
a higher AS is more likely to give more dramatic response to the anti-VEGF treatment with a 
more significant decrease in AS (Figure 4). 
Transferring these data to the clinical applications, it seems logical to treat lesions with an 
AS of 7 or more with anti-VEGF therapy. The high sensitivity (86%) and positive predictive 
values (90%) of the AS strongly suggest retreatment of lesions with an AS of 7 or more. 
However the lower sensitivity and negative predictive values of AS weakly supports 
observation of the ones with lower AS without treatment. The lower rates are most possibly 
because of the lower number of the eyes with less AS who had still been treated with anti-
VEGF. When the number of such eyes had been equal to the treated eyes with higher AS, the 
specificity and negative predictive values of AS might have been higher which would make 
the AS a more reliable measure. 
In addition to routine clinical practice, AS may be used as a standard way of assessment of 
lesion activity especially in clinical studies for the statistical comparison of the results. AS 
may be a valuable tool to see the picture (both the lesion and the response to the treatment) 
as a whole.  
5. Conclusions 
In conclusion, assessment of the lesion activity is important for PRN treatment approaches 
and AS seems to be a standardized measure to assess the activity of the lesion at the 
beginning as well as the treatment effect after anti-VEGF therapy. It may be modified with 
use of some other tools like central field acuity perimetry to be more objective. A lesion with 
an AS of 7 or more seems to be an active lesion which needs treatment and it most possibly 
will give a favorable response to anti-VEGF treatment as a decrease in activity. However, 
the sensitivity and specificity of AS needs to be tested with further studies with larger 
number of patients to be conclusive. Additionally scoring of the lesion activity quantifies the 
lesion activity allowing for statistical comparisons between different treatment methods in 
clinical studies. 
Individualized approaches, on the other side, may be a good option in suitable cases. Re-
injections shortly prior to a recurrence may avoid further growth of the CNV lesion size, 
protecting the neural retina from additional damage and improve the long-term 
prognosis. This may be a better option than PRN approaches preventing recurrences other 
than treating the recurrence. However, this approach requires the ability to determine 
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individual recurrence intervals with a couple of years of experience with PRN regimen 
and some lesions do not obey any rule of periodical recurrence in long term. The results of 
these approaches need to be proven with further randomized controlled studies to be 
conclusive.  
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